Arthur Levin, PhD, Avidity Biosciences, La Jolla, CA, briefly discusses the future of antibody-oligonucleotide conjugates (AOCs) for the treatment of neuromuscular disorders, commenting on the possibility of targeting several different cell surface receptors and using a variety of monoclonal antibodies (mAbs) to deliver therapeutic agents and treat a wide range of diseases. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Disclosures
Dr Levin is an employee of Avidity Biosciences, a Board member at Stoke Therapeutics, and a SAB member at Atalanta Therapeutics.
